Skip to main content
. 2023 Dec 22;8(24):e173688. doi: 10.1172/jci.insight.173688

Figure 2. Low-dose EGFR ligands confer more resistance to ALK inhibitors in MIG6-knockout cells.

Figure 2

(A) JFCR-028-3 cells were treated with the indicated concentrations of drugs and ligands for 72 hours. Cell viability was measured using the CellTiter-Glo assay. Each point represents the mean ± SD of 3 technical replicates; **P < 0.01, ***P < 0.001 (2-way ANOVA following Tukey’s post hoc test). (B and C) Protein expression of the downstream pathway of ALK in JFCR-028-3 cells. Cells were treated with 300 nmol/L of alectinib for 3 hours and 20 ng/mL of EGF for the indicated hours (B) or 10 ng/mL of TGF-α for 3 hours (C). (A–C) Similar experiments were performed twice (B and C) or 3 times (A), and representative data are shown.